NEO-PV-01 + poly-ICLC + nivolumab + ipilimumab

**NEO-PV-01 + poly-ICLC + nivolumab + ipilimumab** is an experimental multi-agent immunotherapy regimen for cancer. It combines: - **NEO-PV-01**: a personalized neoantigen peptide vaccine individually manufactured for each patient based on tumor-specific genetic mutations. It is designed to induce strong, specific T cell immune responses against tumor cells[1][3][5]. - **poly-ICLC**: an immune adjuvant and synthetic double-stranded RNA (Hiltonol), which boosts the vaccine's immunogenicity by stimulating innate immune receptors, such as toll-like receptor 3, enhancing anti-tumor immunity[3][5]. - **nivolumab**: a human IgG4 monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), blocking its signaling and boosting T cell responses against tumor cells[2][3][5][6]. - **ipilimumab**: a monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), removing an inhibitory checkpoint to strengthen T cell activation[2][4][5][6]. This combination is intended to produce robust, multi-modal anti-tumor immune activation: the vaccine primes neoantigen-specific immune reactions, poly-ICLC boosts the vaccine effect, and checkpoint inhibitors (nivolumab and ipilimumab) lift immune suppression, maximizing T cell–mediated tumor destruction. Clinical trials have evaluated this regimen primarily in advanced melanoma, as well as bladder cancer and lung cancer[3][5][7].

Other names

Hiltonol (poly-ICLC)